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Extended-spectrum β lactamases (ESBLs) continue to be a major challenge in clinical setups world over, conferring resistance to
the expanded-spectrum cephalosporins. An attempt was made to study the prevalence of ESBL-producing Klebsiella pneumoniae
clinical isolates in a tertiary care hospital in Kurnool. A total of hundred collected isolates of Klebsiella pneumoniae was studied
for their susceptibility patterns to various antibiotics and detection of ESBL producers by double disc synergy test (DDST) and
phenotypic conﬁrmatory disc diﬀusion test (PCDDT). Of the 100 isolates tested for their antibiogram, 61% isolates have shown
susceptibility to 3rd-generation cepholosporins and 39% were resistant. Amoxycillin showed the highest percentage of resistance
followedbytetracyclins andcotrimoxazole. Among39resistantisolates ofKlebsiellapneumoniae, 17 were ESBL producers detected
byDDSTandPCDDT.ESBLproducersweremoreinthehospitalisolates(28%)comparedtocommunityisolates(6%).Maximum
percentage of ESBL producers were noticed from blood sample with 57.14%. In the present study, a large number of isolates were
found to be multidrug resistant and ESBL producers. PCDDT was found to be better than DDST in the detection of ESBLs.
Continued monitoring of drug resistance is necessary in clinical settings for proper disease management.
1.Introduction
β-Lactam antimicrobial agents represent the most common
treatment for bacterial infections and continue to be the
leading cause of resistance to β-lactam antibiotics among
Gram-negative bacteria worldwide. The persistent exposure
of bacterial strains to a multitude of β-lactams has induced
dynamic and continuous production and mutation of β-
lactamases in these bacteria, expanding their activity even
against the newly developed β-lactam antibiotics. These
enzymes are known as extended-spectrum β-lactamases
(ESBLs) [1–3]. Treatment of these multiple drug-resistant
organisms is a therapeutic challenge. At the level of a
wider geographic scale, the incidence of ESBL-producing
organisms is diﬃcult to determine due to various reasons,
diﬃculty in detecting ESBL production and inconsistencies
in reporting [4]. In recent surveys, a signiﬁcant increase in
theESBLratewasreportedfromallpartsoftheworld[5–12].
Klebsiella pneumoniae and Escherichia coli remain the
major ESBL-producing organisms isolated worldwide [13]
which are recommended to be routinely tested for and re-
ported by the Clinical and Laboratory Standards Institute
[14]. Prevalence of ESBLs varies from an institute to another.
Previous studies from India and abroad have reported ESBL
production varying from 8 to 80%. However, there is paucity
scientiﬁc information available on antibiotic proﬁle with
rate of ESBL production in Klebsiella pneumoniae isolates.
Keeping in view the above facts, the present study was
undertaken to ﬁnd the prevalence of ESBL producers among
Klebsiella pneumoniae isolates at our institute.
GovernmentGeneralHospital,Kurnoolisa1200-bedded
hospital with a daily outpatient turnover of more than 2000.
It is a tertiary care hospital and a referral centre to the hos-
pitals in the surrounding districts. Klebsiella pneumoniae is
oneofthecommonestorganismsassociatedwiththehospital
acquired infections. Hence, the present study is attempted to2 ISRN Microbiology
evaluate the extent of prevalence of ESBL-producing strains
of Klebsiella pneuoniae in the hospital and community along
with antibiotic resistance proﬁle.
2.MaterialsandMethods
This prospective study was conducted in the Department of
Microbiology at Kurnool Medical College, Kurnool, Andhra
Pradesh. A total of 100 isolates were obtained from clinical
samples from January to October 2008. Among 100 isolates,
50 were from out patients and remaining 50 from in patients
admitted into Government General Hospital in units like
medical, surgical, orthopedic, burns, pediatric, neonatal
intensive care units, and acute medical care units.
3.ProcessingofSamples
All samples were inoculated on Mac Conkey’s and Blood
agar, incubated at 37◦C for overnight, and colonies were
processed. In case of blood sample, blood was incubated at
37◦C overnight in Brain Heart infusion broth. A drop of
Brain Heart Infusion broth was inoculated on Mac Conkey
agar and Blood agar and incubated at 37◦C for overnight. If
colonies were not seen even after 7 days, the blood sample
was reported as negative. Colonies in any of these 7 days,
were subcultured. Klebsiella pneumoniae isolates that were
obtainedasapureandpredominantgrowthfromtheclinical
specimens were only considered for the present study. The
organisms were identiﬁed based on colony morphology and
biochemical reactions [15].
4.AntimicrobialSusceptibilityTesting
Routine disc diﬀusion susceptibility testing was performed
by modiﬁed KirbyBauer’s disc diﬀusion method [16].
Various antimicrobial discs were used which include
antimicrobials for screening of ESBL Klebsiella species:
cefotaxime—30μg; ceftazidime—30μg; ceftriaxone—30μg;
amikacin—10μg; amoxycillin—20μg; gentamycin—10μg;
tetracycline—30μg; imipenem—30μg; ciproﬂoxacin—5μg;
aztreonam—30μg; cotrimoxazole—1.25/23.75μg. The
results were interpreted as per the National Committee for
Clinical Laboratory Standards (NCCLS) recommendations
[17]. Klebsiella pneumoniae ATCC 700 603 (ESBL positive)
strain was used as control throughout the study. Isolates with
resistance or with decreased susceptibility (intermediate by
NCCLS criteria) to any of the 3GC were selected for further
study.
5. Screeningof ESBL-ProducingStrains for
Klebsiellapneumoniae
Clinical and Laboratory Standards Institute [14]h a sd e v e l -
oped screening tests for identifying the ESBL-producing
Klebsiellla species. According to CLSI guidelines, strains
showing zone of inhibition of ≤22mm for ceftazidime,
≤27mm for cefotaxime, and ≤25mm for ceftriaxone were
selected for conformational tests of ESBL.
5.1. ESBL Conﬁrmatory Tests
5.1.1. Double Disc Synergy Test (DDST) [18]. The isolated
colonies were inoculated in peptone water at 37◦Cf o r2 – 6h .
The turbidity was adjusted to 0.5Mc Farlands standard and
lawn culture was made on Mueller-Hinton agar using sterile
swab. Augmentin disc (20/10μg) was placed in the centre
of plate. Both side of Augmentin disc, a disc of cefotaxime
(30μg) and ceftazidime (30μg), were placed with centre
to centre distance of 15mm to centrally placed disc. The
plate was incubated at 37◦C overnight. ESBL production
was interpretated as the 3rd-generation cephalosporin disc,
inhibition was increased towards the Augmentin disc or if
neither discs were inhibitory alone but bacterial growth was
inhibited where the two antibiotics were diﬀused together.
5.1.2. Phenotypic Conﬁrmatory Disc Diﬀusion Test (PCDDT)
for ESBL [17]. ESBL production was conﬁrmed among po
-tential ESBL-producing isolates by phenotypic tests. Lawn
culture of the organism was made and 3rd-generation ceph-
alosporins ceftazidime (30μg) disc and ceftazidime + cla-
vulinic acid (30μg+1 0 μg) disc was placed with 25mm
apart. An increase of ≥5mm in zone of inhibition for cef-
tazidime + clavulinic acid compared to ceftazidime was con-
ﬁrmed as ESBL producers.
6. Results
A signiﬁcant diﬀerence in resistant and susceptibility pattern
was observed with 3rd-generation cepolosporins between
hospital and community strains. An antibiogram of the iso-
lates was presented in (Table 1). Of the 100 isolates of Kleb-
siella pneumoniae tested for their antibiogram, 61% isolates
have shown susceptibility to 3rd-generation cepholosporins
and 39% were resistant. Amoxycillin showed the highest per-
centage of resistance (86% in hospital and 76% in commu-
nity) followed by tetracyclins and cotrimoxazole. Similarly, a
highestpercentagesusceptibilitytoimipenam(84%hospital,
96% community) followed by ceftriaxone, cefaperazone +
sulbactum were noticed. In the case of aminoglycosides,
amikacin showed higher percentage of susceptibility (56% in
hospital and 78% in community) compared to gentamycin
(40% in hospital and 62% in community).
Of the 100 clinical isolates of Klebsiella pneumoniae,3 9
were screened according to CLSI guidelines and selected for
conformational tests of ESBL. The two techniques were used
in the present study to conﬁrm ESBL-producing Klebsiella
pneumoniae, namely, DDST and PCDDT and conﬁrmed
28% hospital and 6% community isolates were the ESBL
producers. The results (Table 2) showing that of the 17 Kleb-
siella pneumoniae isolates, 15 isolates were positive by DDST
(88.23%), however, PCDDT shown that all 17 were positive
(100%). Among 17 strains of ESBL-producing Klebsiella
pneumoniae, 3 isolates are resistant to one of the 3GCs, 5 are
against the 2 of the 3GCs, and 9 are resistant to all the 3GCs.
DDST fail to detect ESBL in 2 isolates which showed ESBL
production by PCDDT. There is no instance of a DDST-
positive and PCDDT-negative ESBL producers. This implies
that PCDDT is more sensitive in detecting ESBL productionISRN Microbiology 3
Table 1: Antibiogram of clinical isolates of Klebsiella pneumoniae.
S. no. Name of
antibiotic
Hospital isolates Community isolates
Susceptibility Resistant Susceptibility Resistant
No. of isolates Percentage No. of isolates Percentage No. of isolates Percentage No. of isolates Percentage
(1) Amikacin 28 56% 22 44% 39 78% 11 22%
(2) Gentamycin 20 40% 30 60% 23 62% 27 38%
(3) Ciproﬂoxacin 14 28% 36 72% 19 38% 31 62%
(4) Amoxycillin 7 14% 43 86% 12 24% 38 76%
(5) Ceftazidime 22 44% 28 56% 40 80% 10 20%
(6) Ceftriaxone 28 56% 22 44% 42 84% 8 16%
(7) Cefotaxime 26 52% 24 48% 39 78% 11 22%
(8) Cotrimoxazole 10 20% 40 80% 13 26% 37 74%
(9) Imipenem 42 84% 8 16% 48 96% 2 9%
(10) Aztreonam 15 30% 35 70% 14 28% 36 72%
(11) Cefaperazone
+ Sulbactum
30 62% 20 38% 40 82% 10 18%
(12) Tetracyclin 4 8% 42 84% 12 24% 38 76%
Table 2: ESBL pattern of Klebsiella pneumoniae isolated from various clinical samples.
No. of Klebsiella
pneumoniae
isolates
Hospital
isolates
Community
isolates
No. of screened and
selected isolates for
ESBL conﬁrmatory tests
No. of ESBL conﬁrmed No. of ESBL conﬁrmed by
(39) (17)
Hospital Community Hospital Community DDST PCDDT
100 50 50 30 9 14 (28%) 3 (6%) 15 (88%) 17 (100%)
than DDST. Among 17 conﬁrmed ESBL producers, the Hos-
pital isolates are the major ESBL producers.
7. Discussion
In India, high prevalence of ESBL-producing Klebsiella
pneumoniae strains has been reported by various groups
[19–22]. In the present study, we noticed the prevalence of
ESBL-producing Klebsiella is 17%. The percentage of ESBL-
producing organisms ranged from 4% to 83% in India. The
percentage is lowest in Maharastra reported by Rodrigues et
al. [21] that the 4 (8.5%) positive ESBL producers among 47
Klebsiella pneumoniae isolates. Probably, it reﬂects emerging
phase of ESBL production which by now would have
increased in the same place if a similar study is conducted in
the present time. This is understandable as the prevalence of
ESBLproducersinanyhospitaldependsuponvariousfactors
like antibiotic policy, the carriage rate among the hospital
personal, and the type of disinfection used especially in ICU
[23].ThesehavenotbeenextensivestudiesavailableinIndia.
These strains are often undetectable by routine susceptibility
testing methods. It can be presumed that ESBL-producing
strains are more prevalent than currently recognized.
In the present study, among the 50 nosocomial isolates,
30 isolates were shown resistance to 3GCs (60%). Of these 30
isolates, the 14 showed ESBL production (28%). However,
the percentage of ESBL producers in community isolates
tested was only 6%. The present results were correlated with
that of Shukla et al. [24] reported that 32% of Klebsiella
pneumoniae from 120 samples of tertiary care hospital. Some
of the authors feel that ESBL screening is not likely to aﬀect
the patient outcome and hence neither necessary nor cost,
eﬀective for the laboratories. They also observed good clini-
cal outcome with cephalosporins for treatment of infections
withESBL-producingorganisms.Thisisanargumentagainst
routine screening for ESBL production [25, 26].
In the present study, the highest percentage of ESBL
was reported from blood followed by stool, sputum, urine,
and pus samples (Table 3). A total number of 7 blood sam-
ples were processed from septicemic patients and reported
57.14% samples to have ESBL strains of Klebsiella pneumo-
niae. Similar reports have been recorded in the recent past
by Guptha et al. [27]: from Chandigarh isolated 9 ESBL-
producing Klebsiella pneumoniae from 13 blood samples in
septicemia patients with the percentage of 69.2%. Another
study by Ananthan and Subha [23] has shown 92.85%
ESBL producers from septicemia in a study of 14 cases.
The prevalence of ESBL in septicemia individual has great
importance as most of ESBL Klebsilla pneumoniae are mul-
tidrugresistant.Therewillbegreatlimitationoverthechoice
of drug for treating the septicemia patients. There is 50%
incidence of ESBL production in isolates from stool samples.
Only two Klebsiella pneumoniae isolates could be obtained
from stool samples of admitted patients. Here the sample4 ISRN Microbiology
Table 3: Sa mple wise distribution of ESBL producing Klebsiella pe-
numoniae.
S. no. Sample
No. Klebsiella
pneumoniae
isolates
ESBL producing K. pneumoniae
No. of
isolates Percentage
1 Sputum 42 8 19.04%
2 Urine 23 3 13.04%
3 Pus 16 2 12.05%
4 Blood 7 4 57.14%
5 Stool 2 1 50%
number is quite less and hence percentage does not depict
the exact one. However, the gastrointestinal carriage and
asymptomatic colonization with ESBL producers among
inpatients has been well documented [28].
A signiﬁcant number of ESBL-positive cases are recorded
from sputum samples. Out of 42 sputum samples 8 were
ESBL positive with the percentage of 19.04%. This may
be because many of the sputum samples are taken from
ICU wards. In the present study, 28% ESBLs are reported
from patients admitted into hospital. A study conducted
in Aligarh tertiary care hospital has also reported 30.18%
ESBL Klebsiella pneumonaie from clinical samples [27]. A
study conducted by Ananthan and Subha [23] from Chennai
reported 23.6% of ESBL Klebsiella pneumoniae from clinical
isolates. In other studies, Menon et al. [29] from Chennai
and Supriya et al. [30] from Nagpur have also reported the
prevalence of ESBL producing Klebsiella pneumoniae were
21.2% and 25.65%, respectively.
In recent years, a signiﬁcant increase in ESBL-producing
Klebsiella spp. was also reported from USA 4.2–44% [30–
32] Canada 4.9% [33], Spain 20.8% [9], Taiwan 28.4%
[10], Turkey 78.6% [11], Algeria 20% [12], and China 51%
[34]. Focusing on the epidemiology in Europe, there are
considerable geographical diﬀerences in the occurrence of
ESBLs. A recent large survey of 1610 Escherichia coli and
785K. pneumoniae isolates from 31 centers in 10 European
countries found that the prevalence of ESBL in these
organisms ranged from as low as 1.5% in Germany to as high
as 39–47% in Russia, Poland, and Turkey [35].
Looking at the overall trend of ESBL Klebsiella pneumo-
niaeisontheriseandvariable.Thiscouldpartlybeirrational
use of cephalosporins at some institutions and more number
of blood samples was processed. The actual magnitude of
problem posed by ESBL producers is not known as routine
susceptibility testing fails to detect all ESBL producers. The
two techniques used in the present study to conﬁrm ESBL
production are, namely, DDST and PCDDT. DDST fail to
detect ESBL in 2 isolates which showed ESBL production
by PCDDT. There is no instance of a DDST-positive and
PCDDT-negative ESBL producers. This implies that PCDDT
is more sensitive in detecting ESBL production than DDST.
Looking at all other authors and in the present study, it is
conﬁrmed that PCDDT is more sensitive than DDST for
detection of ESBLs [36–38].
In conclusion, our study highlights the prevalence
of ESBL-producing Klebsiella pneumoniae in Government
General Hospital, Kurnool, having a signiﬁcant percentage.
Routine detection of ESBL-producing microorganisms is
required to be done by each laboratory by the standard
detection methods so as to control the spread of these
infections and also to institute proper therapeutic strategies.
Forthedetection,thephenotypicconﬁrmatorydiscdiﬀusion
test is simple, sensitive, and costeﬀective. However there is a
need to emphasize on the rational use of antimicrobials and
strictly adhere to the concept of “reserve drugs” to minimize
the misuse of available antimicrobials. In addition, regular
antimicrobial susceptibility surveillance is essential.
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